ABIONYX PHARMA SA (ABNX.PA) Stock Price, Forecast & Analysis
Europe - Euronext Paris - EPA:ABNX - FR0012616852 - Common Stock
ABNX.PA Key Statistics, Chart & Performance
The current stock price of ABNX.PA is 4.33 EUR. In the past month the price decreased by -13.4%. In the past year, price increased by 220.74%.
ABNX.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 72.89 | 48.33B | ||
| 1AE.DE | ARGENX SE | 72.72 | 48.22B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 20.56B | ||
| 2X1.DE | ABIVAX SA | N/A | 8.41B | ||
| ABVX.PA | ABIVAX SA | N/A | 8.44B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.76B | ||
| 5CV.DE | CUREVAC NV | 5.09 | 996.15M | ||
| NANO.PA | NANOBIOTIX | N/A | 869.81M | ||
| PHIL.MI | PHILOGEN SPA | 21.14 | 704.68M | ||
| IVA.PA | INVENTIVA SA | N/A | 547.70M | ||
| ALCLS.PA | CELLECTIS | N/A | 453.47M | ||
| FYB.DE | FORMYCON AG | N/A | 423.20M |
Related stock screener links
About ABNX.PA
Company Profile
ABIONYX Pharma SA engages in the in discovery and development of novel therapies for patients without existing or effective treatments. The company is headquartered in Balma, Occitanie and currently employs 51 full-time employees. The company went IPO on 2015-03-30. The Company’s product portfolio comprises Cerenis HDL and HDL enhancers that is designed to regress atherosclerotic plaque among patients at high risk of cardiovascular events, among others. Additionally, the Company has a portfolio of clinical and preclinical HDL programs. The firm is present in Labege in Midi-Pyrenees in France and in Ann Arbor in Michigan in the United States. In addition, it also operates through LYPRO Biosciences Inc.
Company Info
ABIONYX PHARMA SA
Bat. D 33-43 Avenue Georges Pompidou
Balma OCCITANIE FR
Employees: 51
Phone: 33562249706
ABIONYX PHARMA SA / ABNX.PA FAQ
What does ABIONYX PHARMA SA do?
ABIONYX Pharma SA engages in the in discovery and development of novel therapies for patients without existing or effective treatments. The company is headquartered in Balma, Occitanie and currently employs 51 full-time employees. The company went IPO on 2015-03-30. The Company’s product portfolio comprises Cerenis HDL and HDL enhancers that is designed to regress atherosclerotic plaque among patients at high risk of cardiovascular events, among others. Additionally, the Company has a portfolio of clinical and preclinical HDL programs. The firm is present in Labege in Midi-Pyrenees in France and in Ann Arbor in Michigan in the United States. In addition, it also operates through LYPRO Biosciences Inc.
Can you provide the latest stock price for ABIONYX PHARMA SA?
The current stock price of ABNX.PA is 4.33 EUR. The price increased by 4.34% in the last trading session.
Does ABNX stock pay dividends?
ABNX.PA does not pay a dividend.
How is the ChartMill rating for ABIONYX PHARMA SA?
ABNX.PA has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the market expecting ABNX stock to perform?
8 analysts have analysed ABNX.PA and the average price target is 10.97 EUR. This implies a price increase of 153.23% is expected in the next year compared to the current price of 4.33.
Can you provide the PE ratio for ABNX stock?
ABIONYX PHARMA SA (ABNX.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.13).
ABNX.PA Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to ABNX.PA. When comparing the yearly performance of all stocks, ABNX.PA is one of the better performing stocks in the market, outperforming 99.03% of all stocks.
ABNX.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ABNX.PA. While ABNX.PA seems to be doing ok healthwise, there are quite some concerns on its profitability.
ABNX.PA Financial Highlights
Over the last trailing twelve months ABNX.PA reported a non-GAAP Earnings per Share(EPS) of -0.13. The EPS decreased by -23.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -35.2% | ||
| ROE | -83.6% | ||
| Debt/Equity | 0.59 |
ABNX.PA Forecast & Estimates
8 analysts have analysed ABNX.PA and the average price target is 10.97 EUR. This implies a price increase of 153.23% is expected in the next year compared to the current price of 4.33.
For the next year, analysts expect an EPS growth of -68.75% and a revenue growth 4.35% for ABNX.PA